Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | FABP7 | O15540 | 1/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3306289 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2RAB9ANPC1TSHRMIF | |
| SCHEMBL717144 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2RAB9ANPC1TSHRMIF | |
| SCHEMBL2159645 | 0.90 | ALDH1A1 (0.52) | SMN1; SMN2RAB9ANPC1TSHRALDH1A1 | |
| SCHEMBL19204881 | 0.85 | TSHR (0.50) | SMN1; SMN2RAB9ATSHRALDH1A1GAA | |
| SCHEMBL2621303 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2RAB9ANPC1TSHRALDH1A1 | |
| SCHEMBL6666657 | 0.83 | FABP7 (0.58) | SMN1; SMN2RAB9ANPC1TSHRALDH1A1 | |
| SCHEMBL10917021 | 0.83 | FABP7 (0.58) | SMN1; SMN2RAB9ANPC1TSHRALDH1A1 | |
| SCHEMBL280126 | 0.83 | FABP7 (0.58) | SMN1; SMN2RAB9ANPC1TSHRALDH1A1 | |
| SCHEMBL3367169 | 0.82 | FABP7 (0.54) | SMN1; SMN2RAB9ANPC1TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL27765522 | 0.82 | FABP7 (0.57) | SMN1; SMN2RAB9ANPC1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118696041-A | Macrocyclic BTK inhibitors | 克罗斯费尔肿瘤学控股有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20200165218-A1 | METHODS FOR MAKING CYCLOHEXENE OXIDE-CONTAINING ESTERS | ARKEMA INC. | 2020-05-28 | — | — | US | disclosed |
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
| WO-2018038265-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | 田辺三菱製薬株式会社 | 2018-03-01 | — | — | WO | disclosed |
| US-8664414-B2 | Process for producing epoxy compound | SHOWA DENKO K.K. (JP) | 2014-03-04 | — | — | US | disclosed |
| US-8466303-B2 | Process for production of epoxy compound | SHOWA DENKO K.K. (JP) | 2013-06-18 | — | — | US | disclosed |
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| CN-1293057-C | Ethylenediamine derivatives | DAIICHI SEIYAKU CO (JP) | 2007-01-03 | — | — | CN | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| CN-1438993-A | Ethylenediamine derivatives | DAIICHI SEIYAKU CO (JP) | 2003-08-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | SMN1; SMN2 1044/4885RAB9A 3368/4885NPC1 3879/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | SMN1; SMN2 473/4885RAB9A 3294/4885NPC1 3358/4885 |
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | SMN1; SMN2 473/4885RAB9A 3294/4885NPC1 3358/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | SMN1; SMN2 473/4885RAB9A 3294/4885NPC1 3358/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | SMN1; SMN2 473/4885RAB9A 3294/4885NPC1 3358/4885 |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | SMN1; SMN2 2334/4885RAB9A 1086/4885NPC1 2611/4885 |
| US-20200165218-A1 | METHODS FOR MAKING CYCLOHEXENE OXIDE-CONTAINING ESTERS | CBR1, ADH1A, AOX1 | SMN1; SMN2 4237/4885RAB9A 4419/4885NPC1 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.